CIS-DIAMMINEDICHLOROPLATINUM II
Advanced Bile Duct Carcinoma
National Cancer Institute (NCI)Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
14 Active assets in the Advanced Bile Duct Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Capecitabine University of Washington | Phase 1 | CC |
Elimusertib National Cancer Institute (NCI) | Phase 1 | CC |
Ropidoxuridine National Cancer Institute (NCI) | Phase 1 | CC |
cgx1321 Curegenix Inc. | Phase 1 | CC |
177lu-dota-sna040 SmartNuclide Biopharma | Early Phase 1 | C |
View all 16 →
Same molecule, other indications
CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →